4Wealth Advisors
BMRN icon

4Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

4Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$244K Buy
4,079
+173
+4% +$10.9K 0.17% 119
2026
Q2 		$225K Buy
3,906
+26
+0.7% +$1.42K 0.17% 139
2026
Q1 		$213K Buy
3,880
+313
+9% +$18.2K 0.18% 131
2025
Q4 		$212K Buy
+3,567
New +$194K 0.18% 137

Other funds holding BMRN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
ARGA Investment Management
ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

4Wealth Advisors's BMRN Position: Q3 2026 in Review

4Wealth Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 4.4% in Q3 2026, buying an estimated $10.9K and bringing the position to 4,079 shares worth $244K. The position accounts for 0.17% of the portfolio, ranked #119.

4Wealth Advisors first reported a position in BMRN in Q4 2025 and has held it in 4 quarters since. 271 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • 4Wealth Advisors held 4,079 shares of BioMarin Pharmaceuticals worth $244K as of Q3 2026.
  • 4Wealth Advisors bought 173 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $10.9K.
  • BioMarin Pharmaceuticals made up 0.17% of 4Wealth Advisors's portfolio in Q3 2026, its #119 holding.
  • 4Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 271 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on 4Wealth Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.